Heart Disease News and Research

Latest Heart Disease News and Research

Broken heart disease affects women in post menopause period

It seems an infarction, but it's not. It's called Tako-Tsubo syndrome, or stress-induced cardiomyopathy, and it's a rare disease which at first used to be confused with the far more common (and dangerous) cardiac infarction. Patients arrive to the emergency room with the characteristic heart attack symptoms: acute pain in the chest, an electrocardiogram with the typical changes and the release of those enzymes associated with the usual heart disease.

9 Apr 2010

BIBA Research's TAVI report to be released

BIBA Research, the UK-based market research specialists for the medical technology industry, announced today that the latest findings from their Transcatheter Heart Valve report will be released on 26 April. The report covers the data period January-March 2010 and is part of BIBA Research's long-established European Cardiovascular Monitor.

9 Apr 2010

Mayo Clinic researchers to present XOMA 052 data at 101st AACR Annual Meeting

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that researchers from the Mayo Clinic will be presenting data on the use of XOMA's high-affinity antibody to interleukin-1 beta (IL-1 beta), XOMA 052, in myeloma at the 101st Annual Meeting of the American Association of Cancer Research (AACR).

9 Apr 2010

Cordis commences enrollment in safety trial of INCRAFT stent graft system for AAA

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technologies, announced today that the first patients have been enrolled in the INNOVATION trial, which will assess the safety of a new stent graft system, called INCRAFT™, to treat abdominal aortic aneurysm (AAA). An estimated 27 million people worldwide have abdominal aortic aneurysms.

9 Apr 2010

RNAO announces winners of 2010 Awards for Excellence in Health-Care Reporting

The Registered Nurses' Association of Ontario is pleased to announce the recipients of this year's Awards for Excellence in Health-Care Reporting.

9 Apr 2010

Magnetic targeting may enhance effectiveness of stem cell therapies for heart injuries

Researchers at the Cedars-Sinai Heart Institute have found in animals that infusing cardiac-derived stem cells with micro-size particles of iron and then using a magnet to guide those stem cells to the area of the heart damaged in a heart attack boosts the heart's retention of those cells and could increase the therapeutic benefit of stem cell therapy for heart disease.

9 Apr 2010

Scientist develops SAMON system to diagnose apnea-hypopnea sleep syndrome

The sleep study or test is key for diagnosing apnea-hypopnea syndrome but, given its high cost, few resources are earmarked to it. Computer scientist at the University of the Basque Country, Mr Alfredo Burgos, has presented a thesis that aims to solve this problem.

9 Apr 2010

Zeria to market, distribute, and sell HemCon's wound and oral care dressings in Japan

HemCon Medical Technologies, Inc., an innovative developer of advanced medical products, is proud to announce the signing of an exclusive licensing agreement with Zeria Pharmaceuticals Co. Ltd., a leading pharmaceutical and consumer healthcare products company. Through this partnership, Zeria will market, distribute, and sell HemCon's line of revolutionary wound and oral care dressings throughout Japan.

9 Apr 2010

Five-year, $3.7M trial evaluates customized warfarin dosage based on patient genetics

A five-year, $3.7 million clinical trial will investigate how to balance the benefits and risks of warfarin, a drug that helps prevent potentially deadly blood clots.

9 Apr 2010

Omega-3 fatty acids improve nerve regeneration, prevent psychotic disorders and reduce cellular aging

Improving nerve regeneration after corneal surgery, preventing psychotic disorders in those at high risk for them and reducing cellular aging are three emerging benefits of the omega-3 fatty acids found in seafood, according to milestone research described in the April 2010 PUFA Newsletter and Fats of Life online publications for health professionals and consumers, respectively.

9 Apr 2010

Six EDs across New York begin using Rochester RHIO

Axolotl Corp., the nationwide leader in health information exchange (HIE) solutions and services and Rochester RHIO, the regional health information organization connecting medical providers across nine counties in New York, today announced that six emergency departments are using Rochester RHIO to view critical patient information from data providers across the region. Emergency departments (ED) include Clifton Springs, F.F. Thompson, Lakeside Memorial, Rochester General, United Memorial Medical Center, and Wyoming Community Hospitals.

9 Apr 2010

Biosense Webster obtains first Ethics Committee approval for CLARITY study

Biosense Webster announces that this week it has obtained its first Ethics Committee approval for the CLARITY study, comparing the 1-year efficacy, safety and efficiency of CARTO(R) 3 System-guided radiofrequency ablation using the NAVISTAR(R) THERMOCOOL(R) Catheter versus fluoroscopy-guided radiofrequency ablation using the Pulmonary Vein Ablation Catheter(R) (PVAC(R), Ablation Frontiers, Medtronic) in patients with paroxysmal atrial fibrillation.

9 Apr 2010

Blood levels of carbon dioxide may be linked to near death experiences after heart attack

Near death experiences have often been described as “seeing life flash before one’s eyes” or “intense feelings of joy and peace.” Now researchers claim that levels of Carbon Dioxide or CO2 may be the causal link for these sensations. They believe that the CO2 alters the levels of certain chemicals in the brain and makes it see lights at the ends of tunnels or dead loved ones.

9 Apr 2010

PESA CNIC-Santander trial initiative to increase knowledge about cardiovascular diseases

Felipe P-triz, Secretary of State for Research and Emilio Bot-n, President of the Grupo Santander, signed today a milestone agreement giving birth to the PESA (Progression of Early Subclinical Atherosclerosis) CNIC-Santander trial. The project's main goal is to increase the knowledge about cardiovascular diseases.

9 Apr 2010

Idaho man fourth in country to receive Levacor- VAD implant

After receiving only the fourth U.S. implant of a new-generation, Utah-made ventricular assist (VAD ) device, an Idaho man with heart failure is looking forward to resuming an active life following an operation on March 17 at University of Utah Hospital.

9 Apr 2010

As overall cancer rates decline in the U.S., thyroid cancer counters the trend

As overall cancer rates are declining in the United States, thyroid cancer counters the trend. It's being diagnosed more frequently, especially in women. Women are three times more likely than men to develop thyroid cancer.

9 Apr 2010

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Idera Pharmaceuticals, Inc. today presented data from a preclinical study evaluating the mechanism of action of a Toll-like Receptor (TLR) antagonist in a preclinical model of atherosclerosis. The presentation entitled "A novel antagonist of TLR7 and TLR9 exerts anti atherogenic effects in ApoE-/- mouse model of atherosclerosis" (abstract P259) was made by Idera scientists at the American Heart Association conference "Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions" being held April 8-10 in San Francisco, CA.

9 Apr 2010

Svelte Medical Systems' Series A extension financing oversubscribed

Svelte Medical Systems, Inc. is pleased to announce that it has successfully completed the extension of its Series A financing from institutional and private investors including CNF Investments, Apjohn Ventures and the Fischell family. The company's Series A extension was oversubscribed and included an initial investment by Norwich Ventures LP. Norwich Ventures is a seed and early-stage venture capital firm committed to helping entrepreneurs, healthcare professionals and inventors build innovative medical technology companies.

9 Apr 2010

Russia's first implant of SynCardia temporary CardioWest Total Artificial Heart performed on 60-year-old female

On March 23, the Bakoulev Scientific Center for Cardiovascular Surgery (BSCCS) in Moscow performed Russia's first implant of the SynCardia temporary CardioWest™ Total Artificial Heart. The patient, a 60-year-old female suffering from biventricular heart failure, is the world's 850th recipient of the Total Artificial Heart.

9 Apr 2010

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Verio Therapeutics is advancing the work of several of Canada's leading stem cell scientists, including Michael Rudnicki, Ph.D., FRSC, and Lynn Arthur Megeney, Ph.D., who have made breakthrough discoveries relating to muscle and pancreatic regeneration.

9 Apr 2010

Heart Disease News and Research

Latest Heart Disease News and Research

Broken heart disease affects women in post menopause period

BIBA Research's TAVI report to be released

Mayo Clinic researchers to present XOMA 052 data at 101st AACR Annual Meeting

Cordis commences enrollment in safety trial of INCRAFT stent graft system for AAA

RNAO announces winners of 2010 Awards for Excellence in Health-Care Reporting

Magnetic targeting may enhance effectiveness of stem cell therapies for heart injuries

Scientist develops SAMON system to diagnose apnea-hypopnea sleep syndrome

Zeria to market, distribute, and sell HemCon's wound and oral care dressings in Japan

Five-year, $3.7M trial evaluates customized warfarin dosage based on patient genetics

Omega-3 fatty acids improve nerve regeneration, prevent psychotic disorders and reduce cellular aging

Six EDs across New York begin using Rochester RHIO

Biosense Webster obtains first Ethics Committee approval for CLARITY study

Blood levels of carbon dioxide may be linked to near death experiences after heart attack

PESA CNIC-Santander trial initiative to increase knowledge about cardiovascular diseases

Idaho man fourth in country to receive Levacor- VAD implant

As overall cancer rates decline in the U.S., thyroid cancer counters the trend

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Svelte Medical Systems' Series A extension financing oversubscribed

Russia's first implant of SynCardia temporary CardioWest Total Artificial Heart performed on 60-year-old female

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Heart Disease News and Research

Latest Heart Disease News and Research

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Newsletters you may be interested in